Equities research analysts at StockNews.com assumed coverage on shares of NanoViricides (NYSE:NNVC – Get Free Report) in a report issued on Tuesday. The brokerage set a “sell” rating on the stock.
NanoViricides Trading Up 0.9 %
NanoViricides stock opened at $1.15 on Tuesday. NanoViricides has a 1-year low of $1.00 and a 1-year high of $2.00. The firm has a market capitalization of $13.55 million, a price-to-earnings ratio of -1.42 and a beta of 0.67. The firm’s fifty day moving average price is $1.21 and its two-hundred day moving average price is $1.16.
NanoViricides (NYSE:NNVC – Get Free Report) last released its quarterly earnings results on Wednesday, February 14th. The company reported ($0.18) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.01.
NanoViricides Company Profile
NanoViricides, Inc, a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company's product portfolio includes NV-CoV-2, nanoviricide drug which is in phase 1a/1b clinical trails for the treatment of Covid; and NV-CoV-2 Oral Syrup, and NV-CoV-2 Oral Gummies, a semi-solid fixed-dose form which are in phase 1a/1b human clinical trials for enabling body-weight-based dose titration as is required for pediatric cases.
See Also
- Five stocks we like better than NanoViricides
- Stock Sentiment Analysis: How it Works
- High-Yield Texas Instruments Could Hit New Highs Soon
- How to Know Which Cryptocurrency to Buy: A Guide for Investors
- Pagaya Technologies: An AI Fintech That Insiders Are Buying
- Dividend King Proctor & Gamble Is A Buy On Post-Earnings Weakness
- Higher Oil Prices Could Give NextEra’s Stock Earnings a Boost
Receive News & Ratings for NanoViricides Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NanoViricides and related companies with MarketBeat.com's FREE daily email newsletter.
